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Abstract: The scientific and therapeutic development of imiglucerase (Cerezyme®) by 
the Genzyme Corporation is a paradigm case for a critical examination of current trends in 
biotechnology. In this article the authors argue that contemporary interest in treatments for rare 
diseases by major pharmaceutical companies stems in large part from an exception among rarities: 
the astonishing commercial success of Cerezyme. The fortunes of the Genzyme Corporation, 
latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster 
therapy for a single but, as it turns out, propitious ultra-orphan disorder: Gaucher disease.
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Introduction
It is a long-established tradition in medicine to “treasure your exceptions”: the study 
of rare forms of disease is not only informative but also almost invariably instructive. 
Although Gaucher disease was until quite recently an arcane specialism within disparate 
clinical fields including hematology, gastroenterology, pediatrics, and neurology, the 
efficacy of imiglucerase as an augmenting therapy for the hematological and visceral 
aspects of this disease has been transforming. Indeed, when the therapeutic benefits 
of imiglucerase as a vanguard orphan agent were noted by Gaucher patients and their 
physicians worldwide, the commercial treasure in Genzyme’s exceptions rapidly 
lifted the corporation to iconic biotechnological status. As an ultra-orphan biologic, 
imiglucerase and its nonengineered predecessor, alglucerase, are exceptionally costly: 
at their height in 2009, annual revenues for imiglucerase approached $1,800,000,000 
(all figures given in US dollars), but despite a high profit margin, this income was 
obtained from the provision for fewer than 6000 patients worldwide.
While such success speaks for itself, it is salutary to explore the causal and historical 
factors that contribute to victory. The authors contend that had any lysosomal disease 
other than Gaucher disease been the principal object of Roscoe Brady and his col-
leagues’ therapeutic interest, then no treatment for this class of disorders would have 
survived the vicissitudes of development and licensing. As a consequence of choices 
made many decades ago, seven enzyme treatments for lysosomal diseases have received 
marketing approval, and more are in late-stage clinical development. Introduction of 
enzyme therapy for lysosomal diseases internationally has greatly expanded the manu-
facturing expertise in biologics; now a multibillion-dollar industry, this ultra-orphan 
field has captured the interest of several large global corporations.
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Gaucher disease has unique features, which render it an 
ideal target for protein-based therapy, but the scientific odys-
sey that eventually led to effective treatment was circuitous 
and much prolonged. After Brady and collaborators1–3 at 
the National Institutes of Health (NIH) made the scientific 
“proof-of-principle” case with glucocerebrosidase extracted 
from human placentae, modifying the enzyme for in vivo 
targeting, the emerging Genzyme company industrialized 
the manufacture of the enzyme and successfully exploited 
the orphan drug legislation first to develop alglucerase 
(Ceredase®; Genzyme Corporation, Cambridge, MA). It was 
readily shown that macrophage-targeted enzyme therapy is 
strikingly effective in Gaucher disease: thus, a recombinant 
product, imiglucerase (Cerezyme®; Genzyme), obtained from 
genetically engineered eukaryotic cells and similarly modified 
after purification, was soon introduced. With this development 
came a breathtaking economy of scale and high revenues from 
international sales that remain unprecedented in the field of 
orphan diseases. Not only did Genzyme make rapid progress 
with high-level reimbursement for an extremely costly treat-
ment for individuals with an ultrarare disease but also it built 
on its commercial achievement after market authorization 
by continuing contributions to clinical practice and scien-
tific research. The emblematic product, imiglucerase, has 
been joined in the marketplace by biosimilar glycoproteins 
obtained by application of novel genetic engineering tech-
niques; moreover, innovative medicinal chemistry has brought 
orally active molecules with alternative therapeutic actions in 
Gaucher disease credibly within the clinical realm.
The enchanting story of enzyme therapy for Gaucher 
disease has taken several unanticipated turns. In June 
2009, after 2 decades of growth and diversification of its 
commercial base, Genzyme lost the capacity to manufacture 
its core product. A catastrophic series of errors affecting 
the production facility for imiglucerase and other enzymes 
caused the loss of more than a third of the company’s revenue. 
The reputation of the Genzyme Corporation, the world’s 
third-largest biotechnology company was in jeopardy, and 
an unprecedented opportunity arose for market takeover of 
imiglucerase by biosimilar agents. One of these (velaglucerase 
alfa [VPRIV®]; Shire Human Genetic Therapies, St Helier, 
Jersey) has received international marketing authorization, 
and another (taliglucerase alfa; Pfizer Inc, New York, NY, 
and Protalix BioTherepeutics, Carmiel, Israel) is in late-
stage development. Nonetheless, with the partial recovery 
of Genzyme’s facility and the recent acquisition of the 
corporation by Sanofi SA, the extent to which these new 
products can develop or maintain their position within the 
competitive microcosm is unresolved. This article reviews the 
developmental history of enzyme therapy for Gaucher disease 
and discloses the authors’ perceptions of the principles most 
likely to sustain pharmaceutical success in the ultra-orphan 
arena.
Gaucher disease pathogenesis:  
basis for therapeutic effect
Gaucher disease is an inborn error of metabolism that results 
from deficiency of β-glucocerebrosidase (D-glucosyl-N-
acylsphingosine glucohydrolase, EC 3.2.1.45), encoded 
by the human GBA1 gene. The enzyme, a lysosomal 
glycoprotein, is an acid β-glucosidase. The range of 
natural substrates of β-glucocerebrosidase are mixtures of 
N-acyl-sphingosyl-1-O-β-D glucosides with varying acyl 
(fatty acid) and sphingosine moieties, including those like 
glucosylsphingosine that are devoid of fatty acids; the enzyme 
cleaves glucosylceramide (also called glucocerebroside) 
into glucose and ceramide. Glucosylceramide accumulates 
within the lysosomes of cells, particularly macrophages 
and related cells.4,5 Gaucher disease is usually regarded 
as the most common lysosomal storage disease, occurring 
in approximately one in every 75,000 births worldwide.6,7 
Inherited as an autosomal recessive disorder, the condition is 
more prevalent in populations of Ashkenazi Jewish descent: 
according to studies of gene frequency, there are estimated 
to be approximately 20,000 individuals carrying two disease-
related mutations (in trans) in the United States alone; two-
thirds of these are of Ashkenazi origin.8 Not all of these 
individuals will develop symptomatic disease.
For operational purposes in clinical practice, Gaucher 
disease has conventionally been categorized into three 
clinical types. In all affected patients, the disease involves 
the visceral organs, bone marrow, and bone. Type 1 (Online 
Mendelian Inheritance in Man [OMIM] #230800), the 
so-called non-neuronopathic disease, is the most prevalent. It 
is distinguished from types 2 (OMIM #230900) and 3 (OMIM 
#231000) – the acute neuronopathic and subacute neuropathic 
variants, respectively – by the lack of characteristic 
involvement of the brain. However, intermediate phenotypes 
occur, particularly between types 2 and 3.9 In addition, there 
are reports of several neurological manifestations in type 1 
patients that are distinct from the specific features that define 
types 2 and 3.10,11
The 7.6 kb GBA1 gene is located on chromosome 
1q2 and comprises eleven exons. A 5 kb unprocessed 
pseudogene is located 16 kb downstream. More than 200 
distinct GBA gene mutations are listed in the Human Gene 
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Mutation Database (http://www.hgmd.cf.ac.uk/ac/all.php). 
Of these, more than 80% are single nucleotide substitu-
tions. Complex alleles account for approximately 20% of 
mutations.12,13 Three mutant alleles, N370S (c.1226 A . G), 
L444P (c.1448T . C), and 84GG (c.84dupG), are the most 
prevalent.8 On account of its diverse phenotypic variability, 
prediction of disease severity based on genotype is only 
approximate.4,8 Individuals with one N370S allele are pro-
tected against neuronopathic disease, while homozygotes for 
L444P are likely to have neuronopathic features. Rare patho-
logical features may accompany other mutations, such as the 
cardiovascular variant, which occurs in patients homozygous 
for the mutant human D409H allele.14,15
Acid glucocebrosidase activity localizes to the 
luminal side of the lysosomal membrane and shares 
properties with integral membrane proteins. The substrate, 
β-D-glucosylceramide (glucocerebroside), is a component of 
cell membranes and is widely abundant in circulating blood 
cells. The small sphingolipid activator protein, saposin C, 
which is critical for activity of glucocerebrosidase in vivo, 
may present glucocerebroside to the enzyme, as reviewed 
by Locatelli Hoops et al.16 Deficiency of saposin C, which 
occurs only rarely, results in a severe but distinct form of 
Gaucher disease.4,16
In patients affected by Gaucher disease, the deficiency of 
glucosylceramidase leads to accumulation of glucocerebroside 
and other glycolipids within the lysosomes of macrophages 
and other phagocytic cells of the monocyte-macrophage 
lineage. The tissue concentration of these compounds may 
be increased 20–100 times.17 The unacylated congener of 
glucosylceramide, glucosylsphingosine, is particularly 
elevated in patients with neuronopathic Gaucher disease, and 
it may have a role in the pathogenesis of Gaucher disease as 
well as in neurodegeneration.18,19
Macrophages, pathologically engorged with glycolipid 
material, are known as Gaucher cells and are a cardinal fea-
ture of the disease.20,21 In histological preparations stained 
by the Leishman method, Gaucher cells have a characteristic 
histological appearance of wrinkled tissue paper or crumpled 
silk. Membrane-bound inclusions filled with glucocerebro-
side are seen with electron microscopy. Gaucher cells have 
the protein expression profile of the so-called alternatively 
activated macrophage, a phenotype associated with chronic 
inflammation and fibrosis.22
As demonstrated by the effects of hematopoietic stem 
cell (bone marrow) transplantation, the clinical manifesta-
tions of Gaucher disease, with massive visceromegaly, are 
principally an indirect consequence of the accumulation 
of the   pathological macrophages in the spleen, liver, and 
bone marrow. However, pathological lipid accumulation in 
macrophages accounts for less than 2% of the additional 
tissue mass in the liver and spleen; the additional increase 
is attributed to an inflammatory and infiltrative cellular 
response.23 Thrombocytopenia and anemia result from splenic 
sequestration, with a contribution from marrow failure, 
as shown by the long-term evolution of the disease after 
splenectomy. Growth failure, muscle wasting, and pubertal 
delay are features of the more general metabolic effects of 
the complex inflammatory response.24
Several pathological processes occur within bone: 
decreased mineral density, marrow infiltration, and   infarction 
of bone.25 The mechanisms leading to decreased bone 
  mineral density are uncertain, but they may involve failure 
to achieve peak bone mass,26 abnormal osteoclast regulation, 
or   overproduction of cytokines/chemokines27 and proteases28 
by activated macrophages.
In neuronopathic variants of Gaucher disease, profound 
failure of lysosomal sphingolipid breakdown leads to the 
accumulation of toxic macromolecules that originate from 
the rapid turnover of membrane gangliosides in neural cells. 
Occasional Gaucher cells are found in the Virchow-Robin 
spaces and sporadically within deep layers of the cerebral 
cortex and cerebellum. Neuronal death and neuronophagia 
by activated microglia occur in selected midbrain, brainstem, 
and cerebellar nuclei – changes that are accompanied by 
reactive astrogliosis.29,30
Delivery of many soluble lysosomal proteins to the 
  lysosome is mediated by mannose 6-phosphate receptors and 
depends on the trafficking of the receptor to early endosomes 
in a manner requiring the interaction of its cytosolic domain 
with the GGAs (Golgi-localized gamma-ear containing, 
ADP-ribosylation factor binding family of multidomain coat 
proteins). These are highly conserved monomeric clathrin 
adaptor proteins that orchestrate the trafficking of the man-
nose 6-phosphate receptors and other cargo molecules from 
the trans-Golgi network to the endosome-lysosome system. 
When the mannose 6-phosphate pathway is defective, as 
in inclusion-cell (I-cell) disease, some soluble lysosomal 
  proteins continue to traffic to the lysosomes: a protein, 
sortilin, is responsible for the independent targeting and 
has numerous cytosolic binding partners, including GGAs; 
the cytosolic domains of sortilin and mannose 6-phosphate 
  receptors are functionally homologous and they share a com-
mon trafficking mechanism.
Sortilin mediates the trafficking of sphingolipid activator 
proteins, cathepsins D and H, and acid   sphingomyelinase. 
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Renal  podocyte  uptake  of  the  therapeutic  enzyme 
  preparations for Fabry disease is also partly mediated by 
  sortilin.31   However, β-glucocerebrosidase and cathepsins 
K and L reach the   lysosomes by a sortilin-independent 
process.
Once taken up by macrophages, the route of exogenous 
mannose-terminated acid β-glucocerebrosidase to the 
  lysosome and related compartments is distinct from other 
lysosomal enzymes and shows marked cell/tissue   selectivity.32 
In humans it appears to be used principally in the brain and 
kidney as well as in fibroblasts; it is less active in peripheral 
leukocytes. Nascent β-glucocerebrosidase binds via 
specific residues to a chaperone molecule on the lysosomal 
membrane, LIMP-2 – a mannose-6-phosphate-independent 
trafficking receptor for β-glucocerebrosidase. Patients with 
mutations in LIMP-2 develop the action myoclonus–renal 
failure syndrome and there appears to be no involvement 
of the macrophage system; their fibroblasts are deficient 
in acid β-glucosidase activity but the deficient trafficking 
is not apparent in enzymatic assays using preparations of 
peripheral white blood cells. Other mannose-6-phosphate-
independent trafficking receptors for β-glucocerebrosidase 
may be active in human tissues, especially hematopoietic tissues.
Notwithstanding,  the  pathway  for  delivery  of 
β-glucocerebrosidase clearly differs from that utilized by 
many other lysosomal proteins, in which the insulin-like 
growth factor 2/cation-independent mannose 6-phosphate 
receptor or sortilin pathway participates. Therapeutic   delivery 
of exogenous mannose-terminated β-glucocerebrosidase 
appears to follow a unique, high-capacity pathway with speci-
ficity for macrophages, which are an important pathological 
focus in Gaucher disease.
The authors propose that two critical features which 
favor the unique salutary effects of enzyme treatment in 
Gaucher disease are:
1.  Apart from neuronopathic disease, the cells affected by 
storage are of monocyte-macrophage lineage; these infil-
trate the liver, spleen, and bone marrow. Since they are of 
hematopoietic origin and are recruited to sites of disease, 
successful metabolic intervention has the potential to 
reverse the pathological infiltration and arrest ongoing 
tissue and organ damage.
2.  Macrophages display surface lectin-like receptors that 
mediate uptake into intracellular compartments to 
complement the enzyme deficiency and hence effec-
tive targeting to this cell type. Glucocerebrosidase 
appears to be unique in its targeting to lysosome and 
does not follow the well-described pathway of uptake 
for mannose-6-phosphate-receptor first demonstrated 
in acid hydrolases responsible for the degradation of 
glycosaminoglycans (mucopolysaccharides), and defec-
tive in mucolipidosis types 2 and 3 (I-cell disease).
Clinical features and natural history 
of disease
Presentation
Type 1 Gaucher disease is characterized by variability in 
signs, symptoms, severity,24,33 and progression, even among 
siblings with the same genotype and in monozygotic 
twins.34,35 The age of onset also is variable and the mean 
severity of disease shows marked differences among dif-
ferent ethnic groups. In patients from Japan, China, Korea, 
Taiwan, and Thailand, rapidly progressive disease is more 
common and the frequency of severe neurological signs 
(leading to assignment to the neuronopathic types 2 and 3 
disease categories) appears generally to reflect the different 
distribution and occurrence of more disabling mutations in 
the human GBA1 gene in these populations.36–38
The disease becomes manifest in some patients as early as 
the second year of life, whereas others have no clinical signs 
until late in adult life. In patients with one of the most common 
mutations (eg, N370S), the mean age of the development of 
recognizable symptoms is 30 years.39 However, some individuals 
with this genotype remain asymptomatic throughout life, thus 
the frequency of type 1 Gaucher disease is difficult to define.
Symptomatic patients have hepatosplenomegaly, bone 
disease, and bleeding. Fatigue is common and pubertal 
delay, with associated delay in growth,40 is a frequent and 
important finding in children. Bone disease is common in 
patients splenectomized for control of hematological disease 
but who have not received definitive treatment.25
Individual clinical features
Splenomegaly is the most common presenting sign of 
type 1 Gaucher disease. The spleen can enlarge to as much as 
75 times its normal size. Hepatomegaly is almost universal, 
but the liver size increases relatively less than the spleen, with 
volumes usually between one and a half and three times that 
of normal. Hepatic fibrosis can occur, but hepatic failure, 
cirrhosis, and portal hypertension are uncommon, except in 
patients splenectomized in childhood. Cirrhosis in Gaucher 
disease tends to be associated with early splenectomy and, 
unless attributable to coexisting hepatitis virus infection, it 
is characterized by massive lobar fibrosis.41
Hepatosplenomegaly may be asymptomatic or it may 
be associated with early satiety and abdominal complaints 
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(distension, discomfort, pain). Splenic infarction may 
present as acute abdominal pain or pain referred to the 
  shoulder; pathological rupture of the spleen occurs in 
Gaucher disease. Patients may be diagnosed with Gaucher 
disease after splenectomy carried out either in the course 
of investigation of suspected hematological malignancy 
or as a result of splenic rupture. Thrombocytopenia, due 
to splenic pooling and marrow disease, is almost always 
present and the bleeding tendency may occasionally be 
life threatening. Anemia is frequent but is not usually 
as clinically significant or severe as thrombocytopenia. 
Leukopenia with infections due to neutropenia is rarely 
found in patients with access to modern health care, but it 
may complicate extreme hypersplenism and severe disease. 
In occasional patients, a tendency to bleed, particularly in 
the perioperative situation, may result from malfunction of 
platelets that are of normal or near-normal number in the 
circulation, because of an acquired Bernard-Soulier-like 
defect associated with prolonged skin bleeding time; so far, 
this complication appears to occur principally in patients 
after splenectomy.42 Platelets from patients with this defect 
fail to agglutinate in response to ristocetin, despite normal 
platelet surface glycoprotein Ib and plasma von Willebrand 
factor activity. The defect is attributable to a factor, not a 
platelet-specific antibody as in the pseudo-Bernard-Soulier 
condition but probably glucosylceramide or a molecular 
congener present in Gaucher disease plasma, which abolishes 
ristocetin-induced agglutination of normal donor platelets. 
The factor associates loosely with the platelet surface and 
impedes the action of the membrane   glycoprotein Ib-V-IX 
heteromeric complex, which   mediates platelet adhesion to 
the subendothelium and interacts with von Willebrand factor, 
thrombin, and fibrin.
Although it may have severe clinical consequences, the 
acquired Bernard-Soulier-like defect (which is ameliorated by 
enzyme therapy) is a rare complication of Gaucher disease. 
Other potentially significant qualitative platelet abnormalities 
appear to be more prevalent in this condition, even if they are 
of less certain clinical relevance. Recently, Simchen et al43 
have reported a retrospective review of the outcomes of 
45   pregnancies in 20 women with Gaucher disease whose 
  platelet function had been investigated by aggregometry 
and cone and platelet analyses. Six of the women received 
treatment with enzyme during pregnancy. Fourteen out of 
45   deliveries were complicated by   postpartum hemorrhage, 
but neither thrombocytopenia nor enzyme therapy appeared 
to influence this complication. Twelve of the 13 women who 
experienced hemorrhage had impaired platelet   aggregation 
(defined as aggregation below the third percentile of average 
aggregate size), compared with only two of seven   nonbleeders. 
Since 79% of women with impaired cone and platelet aggrega-
tion had hemorrhage after at least one delivery and this was 
significantly greater than the 16.7% of those with normal 
platelet function, it appears that prevalent abnormalities as 
judged by these tests may be predictive for obstetric bleeding – 
a   common complication in type 1 Gaucher disease.
Pancytopenia and its attendant complications may arise 
in Gaucher patients after splenectomy. This usually indicates 
extensive long-standing disease in which the population 
of pathological macrophages extends centrifugally to the 
far reaches of the marrow compartment in the skeleton; 
however, in most instances, definitive enzyme augmentation 
rapidly corrects the associated hematopoietic failure. 
Rarely,   pancytopenia with other characteristic features 
of megaloblastic change may complicate deficiency of 
biologically active cobalamins (vitamin B12), which appears 
to be associated with Gaucher disease.44,45
Before enzyme replacement therapy, splenectomy was 
often required to ameliorate dangerous hypersplenism. 
Splenectomy is not only associated with risks of infection 
but also with particular worsening of several aspects of 
  Gaucher disease: bone disease frequently accelerates;25,46 
severe liver involvement typically causes massive fibrosis, 
portal hypertension, and liver failure;41 lung infiltration47 with 
pulmonary hypertension can progress;48 and in type 3 patients, 
neurological disease has been reported to deteriorate after the 
spleen has been removed.47,49
Skeletal manifestations may be crippling and painful; 
they often have a large impact on activities of daily living.46 
Skeletal disease is characterized by diffuse bone pain, punc-
tuated by painful crises, often resulting in osteonecrosis 
(avascular necrosis) with subsequent joint collapse affecting 
the proximal and distal femur, proximal tibia, and proximal 
humerus. Osteolytic lesions, pathological fractures, vertebral 
compression fractures, and other fragility fractures associated 
with low bone mineral density occur.25
Many affected children grow poorly and have delayed 
puberty. However, in one series, all patients experienced 
spontaneous catch-up growth and over 80% achieved a final 
height within the expected range based upon midparental 
height.50 In the same group of children, puberty was delayed 
in almost two-thirds of 57 patients in whom primary endo-
crine pathology was excluded. Most children with severe 
growth deficiency have severe disease in the viscera.51
Interstitial lung disease is a less common manifestation 
of Gaucher disease.47 It occurs when Gaucher cells infiltrate 
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the alveolar spaces and interstitium. Severe pulmonary 
hypertension occurs infrequently.48 Hepatopulmonary syn-
drome with dyspnea aggravated by sitting up – as a result of 
abnormal vascular shunting in the lungs – occurs principally 
in patients with severe liver disease and in whom the spleen 
has been removed, and it may be associated with pulmonary 
hypertension.41
Pregnancy and labor in Gaucher disease patients present 
additional risks: the pregnant state exacerbates the condition and 
usually leads to worsening thrombocytopenia. Osteonecrosis 
occurs with greater frequency in the puerperium. The position 
in relation to enzyme therapy during pregnancy is considered in 
detail later in this article; close specialist medical supervision 
and monitoring is advised during pregnancy, labor, and the 
puerperium. A review of the literature and of fresh data 
relating to the influence of Gaucher disease on pregnancy 
outcomes, the influence of pregnancy on Gaucher disease, 
and the experience of enzyme therapy in pregnancy52 has 
demonstrated an increased risk of adverse pregnancy outcomes, 
including postpartum hemorrhage and infection. Equally, 
manifestations of Gaucher disease often worsen in pregnancy, 
with expanding organomegaly, falling platelet counts, and an 
increased risk of oseonecrosis, especially in the puerperium.
Gaucher disease is associated with parkinsonian 
syndromes, including parkinsonism with Lewy body 
dementia.53 Glucocerebrosidase mutations in heterozygous 
as well as homozygous forms have been associated with a 
variety of parkinsonian phenotypes; these tend to have an 
earlier onset and are less responsive to dopaminergic agonists 
than “classical” non-Gaucher-associated Parkinson disease.54 
The mechanism underlying this association is unclear, 
but molecular interactions between glucocerebrosidase 
mutants and processing of α-synuclein are strongly 
implicated: β-glucocerebrosidase mutants linked to 
Gaucher disease, Parkinson disease, and Lewy body 
dementia alter α-synuclein processing.55 Overexpression 
of several mutant glucocerebrosidases (including familiar 
Gaucher disease-related molecules such as N370S, L444P, 
D409H, D409V , E235A, and E340A) increased α-synuclein 
expression in cultured neural cell lines, but without altering 
glucocerebrosidase activity; in contrast, overexpression 
of wild-type glucocerebrosidase significantly increased 
glucocerebrosidase activity, as expected, but had mixed 
effects on α-synuclein.56 In cell culture models, the “gain 
of function” toxic effect was mitigated by rapamycin. 
Loss of glucocerebrosidase activity first led to neuronal 
ubiquitinopathy and axonal spheroids – a phenomenon 
that is shared with numerous other lysosomal disorders 
affecting the nervous system. Parkinson disease, an adult 
neurodegenerative disorder, has been linked clinically to 
Gaucher disease, but the mechanistic connection is only 
now becoming apparent. Mazzulli et al57 have shown that 
functional deficiency of glucocerebrosidase in primary 
cultures or human induced pluripotent stem cell neurons, 
caused by glucocerebrosidase mutations that are frequently 
found in Gaucher disease, compromises lysosomal protein 
degradation, causes accumulation of α-synuclein, and 
induces neurotoxicity by mechanisms related to aggregation. 
The new concept here suggests that a positive feedback loop 
of reduced lysosomal function and α-synuclein accumulation 
induces neurodegeneration.
Patients with acute neuronopathic Gaucher disease have 
been classified as type 2 Gaucher disease; there is an early 
onset of bulbar paresis, cranial nerve palsies, opisthotonus, 
spastic paresis with variable hepatosplenomegaly, and usu-
ally mild hematological abnormalities. This acute form of 
Gaucher disease is usually fatal before the age of 2 years, 
with malnutrition and aspiration pneumonia due to recurrent 
seizures and development of a decerebrate state. A perinatal 
lethal form of Gaucher disease, best classified with type 2 
disease, is associated with hydrops fetalis and a defect in the 
ability of skin to retain moisture – “collodion baby.”58,59
Chronic forms of neuronopathic Gaucher disease are 
termed type 3 Gaucher disease. Operationally this may 
be described as progressive neuronopathic disease that is 
not acute and infantile in onset. In practice, type 3 disease 
represents a highly heterogeneous multisystem disorder 
including neurological deficits: it has been divided into 
subtypes. Type 3A Gaucher disease is characterized by 
progressive neurological failure in children with cognitive 
impairment, myoclonic or tonic-clonic epilepsy, supranuclear 
gaze palsies, and ataxia; hepatosplenomegaly is usually mild, 
but the patients succumb to progressive brainstem injury 
or uncontrollable seizures. Patients with type 3B Gaucher 
disease have static supranuclear gaze palsy, usually of 
horizontal but occasionally of vertical type; in contrast to 
type 3A disease, the visceral manifestations are typically 
florid, with severe hepatosplenomegaly, anemia, portal 
hypertension, and extensive osseous manifestations including 
vertebral necrosis and gibbus formation at the upper thoracic 
level. In the untreated state, type 3B patients usually die as a 
result of pulmonary infiltration, uncontrollable hemorrhage, 
or hepatic disease.33
A further unusual variant of chronic neuronopathic 
  Gaucher disease (so-called type 3C) has so far been associ-
ated only with homozygosity for the rare missense mutation 
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in the GBA1 gene leading to formation of a variant D409H 
enzyme.14,15,60 This unique disorder has been reported prin-
cipally in Arab populations, but it has also been described 
in Spain – as well as Mexico, Turkey, Egypt, and the Middle 
East. There is stable oculomotor apraxia with moderate 
splenic enlargement, while liver enlargement and skeletal 
manifestations may not be prominent, but there is disease of 
the cardiac valves, and clinical inspection reveals bilateral 
corneal opacification. Cranial computed tomography scans 
show dilatation of the lateral ventricles with brachycephaly. 
The heart shows progressive thickening and calcification of 
mitral and aortic valves, associated with mitral regurgitation, 
mild aortic insufficiency, or severe aortic stenosis. Isolated 
reports from Japan documented the abnormality in advance 
of mutation analysis.61 Later studies confirmed the occurrence 
of homozygosity for D409H in Japanese patients with this 
Gaucher disease variant.62
Heavy calcification of the valve leaflets, extensive 
  calcification of the entire aortic arch, and involvement of 
the coronary arteries occurs. In several cases, Gaucher cells 
have been demonstrated in the valvular tissue.63 Sudden death 
due to cardiac tachyarrhythmia before surgery for aortic 
valve disease has been reported, and in some cases thicken-
ing and calcification has been noted within the myocardium 
and the descending aorta.64,65 Type 3C disease resembles an 
intermediate syndrome between a glycosphingolipidosis and 
a mucopolysaccharidosis (or a glycoproteinosis), but the 
biochemical explanation for the clinical phenotype remains 
elusive; type 3C Gaucher disease responds incompletely, if 
at all, to enzyme therapy.
Clinical course and life expectancy
The clinical course and life expectancy of type 1 Gaucher 
disease is highly variable. Phenotypic expression cannot 
be reliably predicted by genotype, since severity may vary 
among siblings, even between identical twins.35 The spectrum 
ranges from asymptomatic disease, discovered incidentally 
in elderly adults, to fulminant disease presenting in early 
childhood. The disease is usually progressive, but the rate of 
progression varies. In general, the disease progresses more 
rapidly in those who present at a young age.66 The average 
life expectancy at birth for a patient with type 1 disease in 
the modern era was found to be 68 years, compared with 
77 years in the standard US population. Splenectomized 
and nonsplenectomized patients had a life expectancy of 
64 and 72 years, respectively.67 Symptomatic patients may 
die   prematurely from the consequences of splenectomy, 
severe bone disease, bleeding, infection, liver failure, or 
severe   pulmonary disease.20,67 The consequential effects of 
Parkinson disease are also likely to account for excess deaths. 
In addition, patients with Gaucher disease have long been rec-
ognized to be at increased risk of hematological malignancy, 
especially B-cell lymphomas and multiple myeloma.68,69
Outcome measures
From the early days of its use, it rapidly became clear that 
many cardinal features (notably hematological, visceral, and 
osseous) of Gaucher disease responded to enzyme therapy; 
not only was the disease to a large extent reversible but also 
the improvements could be readily documented. Platelet 
counts and blood hemoglobin concentration reflect disease 
severity in nonsplenectomized patients; their response to 
treatment is easily measured by standard technology.70 The 
liver and spleen enlarge with progression of disease over 
time, and shrink on treatment. Several methods have been 
developed to derive volumetric measurements of liver and 
spleen volumes from magnetic resonance imaging and 
X-ray computed tomography images.71 The infiltration of 
bone   marrow by Gaucher cells imparts a clear signature on 
magnetic resonance imaging of the skeleton as the normal 
fat signal in adult marrow is replaced by a more hydrated cel-
lular infiltrate.72 Bone mineralization density is often reduced 
and salutary responses to treatment are readily documented 
by conventional dual energy X-ray absorptiometry.72–76 
Subjective measures are also revealing; validated clinical 
scores of pain, fatigue, and health-related quality of life are 
sensitive to the evolution and amelioration of disease.77–79
Not only are the cells and tissues that are affected by other 
lysosomal diseases less susceptible to therapeutic augmenta-
tion than the macrophage compartment but also clinically 
articulate responses are not so readily monitored. Hepatosple-
nomegaly is a feature of mucopolysaccharidosis type 1 and 
decreases after treatment with enzyme therapy (laronidase 
[Aldurazyme®; Genzyme]) but, while there might be a slight 
improvement in abdominal discomfort and swelling, there 
is little effect on a premorbid systemic   inflammatory state 
and correction of plasma protein abnormalities with rapidly 
improved blood counts – as seen in Gaucher disease: the skel-
etal and connective tissue abnormalities, and respiratory com-
plications, so much part of mucopolysaccharidosis type 1, are 
not readily ameliorated.80 Furthermore, many patients with 
mucopolysaccharidosis type 1 have impaired neurological 
function, which is beyond correction with enzyme therapy. In 
several clinical trials of enzyme therapies for mucopolysac-
charidoses, especially types 2 and 6,81,82 a composite clinical 
end point has been selected: the 6-minute walk distance. 




Development of imigluceraseDrug Design, Development and Therapy 2012:6
While this provides a single generic measure of overall 
functioning, it is open to difficulties of   interpretation (par-
ticularly in long-established disease) and is unlikely to show 
dramatic therapeutic responses.
Fabry disease provides another example of a disease that 
is challenging to monitor: here the multisystem nature of 
the condition, with effects on the peripheral and autonomic 
nerves, the heart, the skin, the kidney, and the blood vessel 
supply to the brain is difficult to quantify. In the untreated 
state, quality-of-life measures are poor83 and the uncontrolled 
effects of introducing a treatment under such   circumstances 
may be reported to be positive. A strong   placebo effect on 
symptoms was observed in one of the landmark clinical 
trials.84 It would be difficult to suggest that either of the 
enzyme treatments radically improves the disease, and a useful 
long-term effect is difficult to determine: renal glomerular 
function may show evidence of “  stabilization,” or inferentially 
a decreased rate of decline, but during the course of therapy 
patients may become deaf or they may spontaneously suffer 
a severe stroke or life-threatening cardiac arrhythmia.85
Credible outcome measures enhance the development of 
treatments, through easier design and implementation of and 
recruitment to clinical trials. But more work on the natural 
course of these rare diseases and innovative trial designs that 
examine time-to-event and other aspects of pathology, which 
may be predicted to respond to the intervention, is needed.
Easy concepts and trials
The concept of enzyme replacement
Once the nature of the enzyme defect in Gaucher disease 
was known, Brady et al86 advanced the notion of a treatment 
that would involve parenteral supplementation of the   purified 
enzyme protein. Although it was not known until 1968 
that β-glucocerebrosidase was a lysosomal enzyme,87 in 
this Brady et al86 followed the discoverer of the lysosome, 
  Christian de Duve,88 (see also Appelmans et al89) who 
predicted that because of its central role in pinocytosis, 
autophagy, and phagocytosis, the lysosomal compartment 
in cells may be readily accessed from the extracellular 
space. This initially vague concept was reinforced by the 
demonstration by Fratantoni et al90 of cross-correction of 
lysosomal enzyme deficiencies that lead to impaired digestion 
of mucopolysaccharides in fibroblasts cultured from patients 
with Hurler and Hunter diseases (mucopolysaccharidosis 
types 1 and 2, respectively). The cross-corrective factors 
were quickly shown to be high-molecular-weight forms of 
the enzymes normally responsible for specific degradative 
steps that were lacking in the disease; the proteins were 
reciprocally secreted into the medium by nondeficient cells 
and were taken up from the medium by deficient cells, in 
which they were targeted to the lysosomal compartment and 
thus functionally correcting the genetic defect.
Although the lysosomal nature of β-glucocerebrosidase, 
which is deficient in Gaucher disease, was shown in 1968,87 
the glycoprotein nature of this enzyme was not at first 
  appreciated. Studies in I-cell disease by Hickman et al91 
revealed the key observation that although fibroblasts 
cultured from patients with I-cell disease could readily 
incorporate enzymes secreted by healthy fibroblasts, the 
enzymes secreted by I-cell fibroblasts could not be taken 
up by other cells. Research by Elizabeth Neufeld, William 
Sly, their colleagues, and other investigators showed that the 
corrective factors in the mucopolysaccharidoses and several 
other lysosomal diseases were phosphohexosyl glycoforms 
of the deficient enzymes in these disorders.92,93 Mannose 
6-phosphate residues displayed on N-glycans were found to 
be a common lysosomal protein recognition signal. Later, the 
groups of Stuart Kornfeld94 and Kurt Von Figura95 isolated 
the endo-H-sensitive N-glycans from nascent lysosomal 
enzymes: these precursor molecules harbored the predicted 
phosphate esters on mannose groups but were blocked by 
outer α-linked N-acetylglucosamine residues. Studies of the 
biosynthetic intermediates in   lysosomal glycoprotein forma-
tion allowed the mechanism by which phosphomonoesters 
of mannose 6-phosphate are introduced into the molecules 
and decorate a large class of newly synthesized enzymes 
destined for the lysosome – and which can be delivered to 
the organelle from sources external to the cell by endocytosis 
mediated by mannose 6-phosphate receptors.94
However, while the phosphomannosyl ligand is operative 
for many lysosomal proteins, studies of the biosynthesis 
of lysosomal glucocerebrosidase have shown that it is not 
subject to these post-translational modifications and does 
not enter the lysosome through the mannose 6-phosphate 
receptor-mediated pathway.96 The existence of a novel chap-
erone molecule, the lysosomal membrane protein LIMP-2, 
which mediates delivery of nascent glucocerebrosidase to 
the organelle in many but not all tissues, has recently been 
identified.32
Early clinical studies
Investigations into the use of enzyme therapy for Gaucher 
disease required an abundant supply of active enzyme 
purified from human sources. Two groups developed 
purification techniques with a view to therapy. Brady 
and colleagues (particularly Peter Pentchev)97 developed 
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a purification scheme that was adapted further for large-
scale use by Scott Furbish (Furbish et al98). One of people 
involved in the work of Furbish et al98 was Henry E Blair of 
the New England Enzyme Center, based at Tufts University, 
Boston, and later a cofounder of the Genzyme Corporation 
and senior vice president of scientific affairs from 1981 to 
1990.   Simultaneously, Ernest Beutler (see Dale and Beutler99 
and Dale et al100) showed that glucocerebrosidase could also 
be purified from placenta using acetone, without the 70% 
loss of enzyme   activity associated with Pentchev’s method,97 
based on detergent extraction, and hydrophobic interac-
tion chromatography. However, the acetone-solubilized 
glucocerebrosidase had an absolute requirement for acidic 
phospholipids for its activity. Nonetheless, the development 
of a large-scale modified procedure for the purification of 
human glucocerebrosidase with a high specific activity 
(.108 units/mg of protein) from human placenta proved to 
be decisive. The method employed extraction with cholate, 
salt fractionation, acid precipitation, butanol extraction, and 
hydrophobic chromatography.98
With protein of sufficient quantity and purity, experimental 
studies – including preliminary clinical trials in patients 
with Gaucher disease – could be undertaken in earnest. 
A key question was whether infusion of the purified 
glucocerebrosidase would dispose of excess glucocerebroside. 
The enzyme was given intravenously into two splenectomized 
patients with Gaucher disease and needle biopsy samples of 
liver were obtained before and 24 hours after the infusion. 
A 15-year-old boy with type 3 Gaucher disease and 
glucocerebroside 0.702 ng/g wet weight of liver (a 22-fold 
increase) received a single infusion of 1.5 mg (25 IU) of 
purified glucocerebrosidase (0.47 IU/kg). A 51-year-old 
woman with type 1 Gaucher disease and pretreatment hepatic 
glucocerebroside of 1.634 ng/g wet weight (∼35 times the 
normal value for females) also received glucocerebrosidase 
(3.3 mg [55 IU]) in equally divided doses on 2 consecutive 
days (0.97 IU/kg). Analysis of glucocerebroside in liver 
biopsy specimens obtained 24 hours after infusion of the 
enzyme revealed that there had been a 26% reduction of this 
lipid in the recipients and that other lipids were unchanged. 
The two recipients tolerated the infusions well, and neither 
had adverse reactions to the placental enzyme.97 Subsequent 
infusions of human placental glucocerebrosidase for the 
woman with type 1 Gaucher disease also induced no signs of 
sensitization. The following year, 9.3 mg (155 IU, 2.5 IU/kg) 
of glucocerebrosidase was infused into a young woman with 
type 1 Gaucher disease and glucocerebroside 17.9 ng/g wet 
weight of liver (∼400-fold increase); however, the relative 
reduction was only 8%, and the amount of glucocerebroside 
cleared from the liver per unit of enzyme activity administered 
was essentially the same in all three of these subjects.101
It soon was apparent that human placental glucocerebro-
sidase prepared by large-scale hydrophobic chromatography 
had inconsistent clinical effects and in experimental studies 
conducted with animals it was shown to have poor delivery 
of parenterally administered enzyme to nonparenchymal 
(principally Kupffer) cells in the liver.102 Given that the 
crude placental enzyme required delipidation by n-butanol 
  treatment to ensure its affinity for the hydrophobic   interaction 
chromatography, it seems likely that this led variably to 
denaturation.
A modified purification procedure for human gluco-
cerebrosidase, taking advantage of the hydrophobicity of 
glucocerebrosidase, was later developed.98 However, when 
the enzyme prepared by this new procedure was infused 
into two young males with Gaucher disease, the reduction 
in hepatic glucocerebroside was disappointing.103 In studies 
with additional patients, inconsistent reductions in hepatic 
glucocerebroside were observed.
Using the purified enzyme obtained from placentae, 
  Morrone et al104 (including Pentchev) found rapid clearance 
from the circulation when infused into rats. Uptake was 
found to be dominant in hepatocytes, with significant deliv-
ery to sinusoidal cells, but included endothelial and Kupffer 
cells. The uptake into all liver cell types was inhibited by 
mannose-containing glycoproteins, even though the enzyme 
was unmodified and hepatocytes were not believed to express 
receptors for uptake of mannose-terminated glycoproteins.
Dale and Beutler99 attempted to engineer delivery to 
macrophages by embedding purified glucocerebrosidase 
in erythrocytes. A trial of this form of enzyme therapy in 
a single patient had marginal effects.105 The technique was 
further refined by coating the erythrocytes with γ-globulin 
to improve delivery of enzyme, through phagocytosis, to 
monocytes and related cells.106 As it turned out, this approach 
by Beutler at Scripps Clinic (La Jolla, CA) failed to generate 
a successful treatment and was overshadowed by findings 
at the NIH by Brady and colleagues.
Carbohydrate remodeling
While these preliminary clinical studies were being con-
ducted, cognate research into the mechanisms that deter-
mined hepatic uptake of circulating glycoproteins was also 
bearing fruit elsewhere in the NIH with the discovery by 
Gilbert Ashwell and his colleague Anatol Morrell of the 
asialoglycoprotein receptor (see Hudgin et al107).
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At the time, there was an intensive research focus into 
the possibility of complementing lysosomal defects in 
inborn diseases of the lysosome by supplying corrective 
enzymes. As already outlined, the general stratagem of 
complementing lysosomal enzyme deficiencies was initiated 
in another   laboratory at the NIH under the direction of 
Neufeld.108 However, the seminal discovery of the mannose-
binding lectin of the macrophage by Philip Stahl et al109 
at Washington University, St Louis, MI, was the critical 
breakthrough. This revelation focused attention on delivery 
of proteins to be explored for therapeutic purposes in 
Gaucher disease – in which the prime cellular target is the 
eponymous macrophage.110 In vivo and laboratory studies 
also carried out at this time in St Louis by William Sly and 
colleagues (see Achord et al111) with different glycoforms 
of acid β-glucuronidase, which is deficient in the lysosomal 
disease mucopolysaccharidosis type 7 (Sly disease), led to the 
practical realization that the mannose/lectin receptor could 
be utilized efficiently to target human glucocerebrosidase 
to macrophages in Gaucher disease after modification of its 
carbohydrate residues.
Once it was appreciated that human glucocerebrosidase 
was a glycoprotein, investigations were undertaken over 
several years to characterize thoroughly its carbohydrate 
composition and behavior.112 Carbohydrate analysis of the 
placental enzyme showed that the enzyme contained both 
high-mannose-type oligosaccharides and a series of trian-
tennary and biantennary complex-type oligosaccharides. 
Complex-type oligosaccharides with incomplete outer chains 
were also found. This contrasts with other lysosomal enzymes 
such as β-glucuronidase and cathepsin D in which only high-
mannose-type oligosaccharides are found. Although some 
of the biantennary sugar chains of the glucocerebrosidase 
had incomplete outer chains with N-acetylglucosamine or 
mannose terminals (13%), efficient endocytosis mediated 
by specific receptors for these sugars does not occur, since 
only weak monovalent interactions with the oligomannose 
chains on one of the four glycosylation sites of the enzyme 
are possible. Three of the side chains were of the complex 
oligosaccharide type – principally terminating with sialyl 
and galactosyl groups. When administered intravenously in 
living rats, up to 98% of these glycoforms of glucocerebro-
sidase was taken up by liver parenchymal cells – rather than 
the nonparenchymal cells, of which Kupffer cells (hepatic 
macrophages) were the desired target.113 Preferential uptake 
by hepatocytes can plausibly be attributed to the asialogly-
coprotein receptor, which has a high affinity for galactose-
terminated glycoproteins.114
The carbohydrate display on the protein was modified 
by sequential deglycosylation to reveal terminal mannose 
residues.115 At first, this apparently cumbersome enzymatic 
deglycosylation approach was not favored. Instead, linear 
pentamannosyl residues were covalently linked to glucocer-
ebrosidase, but this chemical modification failed to enhance 
delivery of the glycoprotein to macrophages in experimental 
animals. Subsequent linking of trimannosyl-dilysyl residues 
to glucocerebrosidase induced a fourfold enhancement of 
uptake by macrophage-rich cells populations, but this was 
not considered to be sufficient to secure a salutary clinical 
effect in living patients with Gaucher disease.116 Ultimately 
sequential enzymatic remodeling of the native placental 
glucocerebrosidase was revived to generate mannose-
terminated enzyme – a modification that greatly increased 
the delivery of glucocerebrosidase to nonparenchymal cells 
in rat hepatocytes.115
Sequential remodeling of the three complex N-linked 
glycosylation sites to expose the core mannose residues on 
human placental β-glucocerebrosidase for subsequent clinical 
development was achieved by serial treatment with neuramin-
idase, β-galactosidase, and β-N-acetylglucosaminidase, 
using specific exoglycosidases purified from the jack bean 
(Canavalia ensiformis).117
The success of this stratagem was contributed to by the 
discoveries of Ashwell at the NIH and of Stahl and Sly and 
their colleagues107,109,111 at the Washington University School 
of Medicine, St Louis, MI; the success of the research later 
engaged several groups and intensified clinical investigation 
generally into the targeted delivery of several therapeutic 
enzymes to their site of action in the lysosome.118
Early clinical trials and development
Efficacy studies of macrophage-targeted 
glucocerebrosidase
Ultimately a strong clinical programe using remodeled 
human placental glucocerebrosidase for Gaucher disease was 
advanced by Norman Barton, John Barranger working with 
Scott Furbish, Peter Pentchev, and Gary Murray in Dr Roscoe 
Brady’s laboratory at the NIH. At the time, no credible or 
tractable animal model of Gaucher disease existed and, as a 
result, proof-of-concept studies for clinical application were 
carried out in patients. The enzymatically modified (mannose-
terminated) human placental glucocerebrosidase was admin-
istered intravenously to eight patients with type 1 Gaucher 
disease. Approximately 190 IU of the protein were infused on 
a weekly basis for 6 months. A striking response was observed 
in a 6-year-old boy, the smallest and youngest trial participant 
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and the only subject to be reported.1 After a few months of 
treatment at a weekly dose in the range of 12–15 IU/kg of body 
weight, there was a marked increase in hemoglobin concentra-
tion, from severely anemic values to a level near the healthy 
reference range. After 6 months of enzyme therapy, the platelet 
count also rose significantly. To determine beyond reasonable 
doubt whether these salutary changes were attributable to the 
intervention, the infusions were temporarily discontinued and 
after cessation of the infusions, the hemoglobin gradually 
declined to the pre-infusion concentration. The platelet count 
also decreased during the period without glucocerebrosidase 
treatment. Thereafter, infusions of macrophage-targeted 
human placental glucocerebrosidase were resumed with 
weekly administration at an augmented dose of 30 IU/kg of 
body weight. The hemoglobin concentration increased more 
rapidly than after the previous infusions at the smaller dose.2 
Administration of glucocerebrosidase was continued over the 
next 48 months. During this interval, liver and spleen size con-
tinued to diminish (spleen decreased significantly), and there 
was radiological evidence of improvement in the   skeleton. 
Given the size of this patient, the investigators   eventually 
deduced that the reason for the spectacular response in this 
individual was that he received more of the enzyme on the 
basis of size than any other trial participant.
In the light of the promising findings in this single 
patient, aged 6 years (who today is married and a healthy 
parent), an explorative dose-response study was undertaken 
with determinations of hepatic glucocerebroside after single 
infusions of macrophage-targeted β-glucocerebrosidase at 
various doses. The information gained from this study led 
to the realization that to obtain significant clinical benefit 
within a 6-month period in nonsplenectomized patients 
with Gaucher disease, administration of 60 IU of modified 
glucocerebrosidase per kilogram of body weight every other 
week would be advisable.
The pivotal clinical trial by Norman Barton and collabora-
tors to investigate therapeutic efficacy of mannose-terminated 
glucocerebrosidase enrolled just twelve patients with intact 
spleens and moderate to severe type 1 Gaucher disease. Each 
patient received 60 IU/kg of macrophage-targeted human 
  placental glucocerebrosidase by intravenous infusion on alter-
nate weeks. Four of the patients were adults and eight were 
children; there were seven females and five males in the trial. 
Twelve other mild type 1 Gaucher disease patients with intact 
spleens, and who were not treated with enzyme augmentation, 
were subject to parallel monitoring, but the patients were not 
matched by age, sex, or clinical severity of disease. Infusions 
of   macrophage-targeted   glucocerebrosidase every other 
week increased the   hemoglobin concentration of all the trial 
recipients. By 6 months, the hemoglobin concentration had 
increased in all the patients (P , 0.003) After 9–12 months of 
treatment, the hemoglobin concentration had risen to within 
the normal reference range in seven of the recipients.3
In the control (noninfused) patients, hemoglobin con-
centrations persistently declined. A significant increase in 
platelet count was noted by 6 months in seven of ten throm-
bocytopenic patients who received the macrophage-targeted 
preparation of glucocerebrosidase. In two of the twelve 
patients with normal platelet counts at the start of this trial, 
the platelets remained within the healthy reference range 
during the investigation. Platelet counts rose to normal in 
two of the recipients after 21 and 37 infusions. No patient 
in the group not in receipt of enzyme had an increase in 
platelet count. As the enzyme infusions continued, further 
salutary increases in the platelet count were noted. Spleen 
volume (a key therapeutic end point and efficacy marker) 
reduced by a mean of 33% (range 14%–75%) in all patients 
after treatment for 6 months, while splenic volume increased 
in three of the noninfused patients over the 6-month period 
of observation. Hepatic volume decreased significantly in 
most patients receiving the enzyme but was unchanged 
in those who were untreated. Finally, early indications of 
skeletal improvement were observed in just 6 months.3 It is 
notable that during subsequent observations over 2 years, 
there was continuing evidence of disease amelioration 
with improved blood counts, well-being, and resolution of 
  hepatosplenomegaly. Signs of skeletal improvement were 
also apparent in the young boy in the previous pilot study: 
replacement of the extensive infiltrate of Gaucher cells in 
his bone marrow with normal marrow progenitors probably 
accounted for the main salutary effects.119
A notable feature of these early trials was the absence of 
untoward side effects or adverse reactions; during the pivotal 
clinical efficacy study, the treatment induced no antibody 
responses to the exogenous glucocerebrosidase.120 Later, in a 
larger cohort of patients treated repeatedly with macrophage-
targeted glucocerebrosidase (alglucerase [Ceredase]), ∼15% 
developed IgG antibodies to this preparation. Notwithstanding 
the emergence of the antibody response, the efficacy of the 
enzyme appeared to be unimpaired, and unwanted clinical 
effects proved to be scarce.121
The clinical efficacy of enzyme therapy using human 
placental glucocerebrosidase modified to reveal terminal 
mannose residues by sequential deglycosylation in patients 
with type 1 Gaucher disease was promptly confirmed by 
other investigators.122–124
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Given the contemporary regulatory environment and 
justified alarm about transmission of hepatitis viruses 
B and C from human-derived blood coagulation products 
in hemophilia syndromes, as well as cases of new variant 
Creutzfeldt-Jakob disease resulting from the administration 
of growth hormone extracted from pooled human pituitary 
tissue, it is remarkable that Genzyme, the NIH, and the 
Gaucher community were not part of a similar catastrophe. 
In fact, given the unprecedented international scale of the 
operation to obtain the starting material, involving thou-
sands of metric tons of human placentae worldwide, the 
largely untrammeled success of Ceredase is little short of 
miraculous. With a small yield, to obtain sufficient protein 
to treat an adult with Gaucher disease required several 
hundred metric tons of placentae each year. At the height 
of the manufacturing effort for Ceredase, placentae from 
about one-third of the world’s births found their way to the 
tissue banks of the Pasteur Mérieux of Lyon, France (pers 
comm; Alan Smith, Cambridge, UK, 2006). Pasteur Mérieux 
(a subsidiary of Rhône-Poulenc at the time) extracted human 
immunoglobulin from the tissue, after which the residue was 
obtained by Genzyme for entry into a multistep extraction 
procedure, followed by exposure to the three exoglycosidases 
to remodel the protein for the manufacture of alglucerase 
(Ceredase). In fact, the French vaccines and blood products 
group suspended the distribution of several immunoglobu-
lin products used in the treatment of allergy, hepatitis, and 
immunoglobulin deficiency in France in 1992, following 
recommendations of the Ministry of Health in relation to 
hepatitis C virus infection.
Clearly in this context there was an immense incentive 
for Genzyme to develop a potentially safer, genetically 
engineered product with consistent quality control and 
availability of supply. Treatment (and the supply) of modified 
human placental glucocerebrosidase was maintained over 
several years until a successor, the recombinant product 
(imiglucerase [Cerezyme]) obtained from genetically 
engineered Chinese hamster ovary cells, was developed 
intramurally and approved for and introduced to the 
international market in 1995.
Recombinant human glucocerebrosidase expressed in 
genetically engineered Chinese hamster ovary cells and then 
remodeled to display terminal mannose residues by sequential 
treatment with plant exoglycosidases has been shown to be 
as effective as the macrophage-targeted placental enzyme in 
clinical trials.125 Studies using carrier-free 123I-radio-labeled 
human preparations of placental glucocerebrosidase and the 
recombinant protein obtained from Chinese hamster ovary 
cell lines in patients with Gaucher disease showed striking 
uptake and distribution of these protein preparations to 
the macrophage-rich viscera and bone marrow.126 In effect 
the plasma disappearance of the isotope and its uptake in the 
affected viscera and bone marrow was rapid, but the remod-
eled enzymes appeared to dwell within affected visceral 
organs over several days. No significant difference in the 
pharmacodynamics and in vivo targeting behavior of these 
modified proteins was identified (alglucerase and imigluc-
erase, respectively). The two mannose-terminated prepara-
tions were also later shown to have similar   pharmacological 
characteristics in normal mice.127
Natural human β-glucosylceramidase (glucocerebrosidase) 
has four glycosylation sites and 22 lysine residues, 
but the recombinantly produced enzyme (imiglucerase 
[  Cerezyme]) differs slightly from placental enzyme 
(alglucerase [Ceredase]) according to the amino acid 
sequence at position 495, where an arginine has been 
replaced by a histidine. This amino acid change appears to 
have little effect on activity and biological behavior. The 
oligosaccharide composition differs between the recombinant 
and the placental enzymes: alglucerase has more fucose and 
N-acetylglucosamine residues, while imiglucerase retains 
one high-mannose chain. As has been explained, both 
preparations are treated sequentially with three different 
exoglycosidases (neuraminidase, β-galactosidase, and β-N-
acetylglucosaminidase) to expose terminal mannoses, which 
facilitates targeting and uptake by cells of the mononuclear-
phagocyte system. A pharmaceutical preparation of the 
recombinantly produced enzyme is described by Genzyme 
in United States patent No 5,549,892.
Clinical development program
Production of modified human placental 
β-glucocerebrosidase (alglucerase)  
for clinical use
Ceredase and, later, Cerezyme were not only effective and 
safe drugs but also they were a striking commercial   success. 
Genzyme created a unique market by forging careful rela-
tionships between treating physicians and patients, and 
often through supporting patient organizations financially 
and with setup assistance. The pivotal trial of alglucerase 
paved the way since most of the funds were not from the 
company: support came for the developmental and trial 
costs from the NIH and in the form of a substantial donation 
(∼$3 million) from the National Gaucher Foundation – the 
premier   Gaucher charity in the United States. Genzyme has 
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continued to   interact profitably with its partners and patient 
organizations and supports single meetings with narrow 
subject areas (such as Gaucher disease) of which it has been 
the sole sponsor or organizer.
The company took the excellent opportunities for protocol 
advice, prelicensing concessions, and marketing exclusiv-
ity offered by the orphan medicinal product legislation in 
the United States, Australia, and Japan – and latterly, on 
its inception in Europe after 2000, for Cerezyme in type 3 
Gaucher disease.
The successful education and reimbursement programs 
set up by Genzyme allowed the company to rise to the high-
est positions in the orphan drug market. This position was 
maintained through Gaucher disease until 2009, when the 
misfortunes that struck the company and its reputation led to 
market loss in the face of emerging biologic competitors.
Early questions of cost
The placenta-derived product alglucerase (Ceredase) clearly 
required massive investment in harvesting and transport 
of placentae, industrial scale purification of the enzyme, 
and carbohydrate remodeling. The annual requirement for 
placentae for each patient’s treatment amounted to about 
50,000 individual placentae (10–12 metric tons), depending 
on dose.125 Treatment for a thousand patients overall required 
about 50 million placentae, plus the means to harvest, store, 
transport, and process them. The cost of Ceredase was many 
times greater than that of other medications. Funding authori-
ties in many countries were either unable to support its use 
or required onerous case-by-case application.
As the drug was priced per unit of enzyme activity, the 
question of cost soon became partly a question of dose. Two 
approaches emerged. As the initial clinical trial had demon-
strated effectiveness at a dose of 60 U/kg of body weight every 
other week, this was the dose recommended in the summary 
of product characteristics. Many physicians, particularly in 
countries where funding allowed it, followed this guidance. In 
countries where funding was more difficult, physicians were 
often led by the arguments of Beutler, that on pharmacokinetic 
and pharmacodynamic grounds, lower but more frequent 
doses – 2–3 U/kg two to three times per week – would be 
equally effective. Many clinical reports and case series attested 
to improvements in hematological parameters and organ size 
with the low-dose regimen.128,129 Discussions between the two 
approaches were often heated.130,131
Barton et al1,2 reported different rates of response in a single 
child when treated with initially lower-1 and later, higher-dos-
age2 regimens. Several developments have allowed a synthesis 
of the two approaches. The availability of informative and 
responsive disease markers permitted adjustment of dose, up 
if required or down as tolerated.132 The general acceptance of 
published therapeutic goals of treatment, based on realisti-
cally achievable outcomes133,134 allowed physicians to aim for 
agreed outcomes for the patient, adjusting the dose if needed 
to achieve these goals. Studies based on registry data have 
examined the dose-response relationship, establishing fairly 
conclusively that a dose-response relationship exists within 
the range of commonly prescribed doses.135 The argument 
has now shifted from whether there is a dose-response rela-
tionship to questions as to whether any benefits of increased 
dose are clinically useful or cost-effective.
The cost of the recombinant product Cerezyme was set 
in most regions to be the same as that of Ceredase. The argu-
ments justifying the expense of the treatment may have 
emphasized the cost of  production in early years, but they 
have more recently been based on the rarity of the condi-
tion and the requirement to support the development costs 
of the treatment, costs that are arguably similar to the costs 
of developing a treatment for a common disease. The cost of 
the treatment has captivated the interest of health economists. 
Despite the clearly life-transforming nature of the enzyme 
therapy for many patients, estimates of the cost-effectiveness 
of the medication, based on generally used techniques such 
as the quality-adjusted life year, have indicated that the cost 
of imiglucerase per unit of health gain greatly exceeds the 
thresholds commonly used to determine whether a treatment is 
economic.136,137 The counterargument is based on the inevitabil-
ity that treatments for rare diseases will be costly and that there 
is a societal duty to care for individuals with rare diseases who 
would otherwise never have access to specific treatments.138
Development of the recombinant product
The genetically engineered human enzyme variant imiglu-
cerase (Cerezyme) is expressed in mutant Chinese hamster 
ovary cells of a strain such as Lec1, in which recombinant 
glycoproteins are synthesized with N-glycans with mannose 
residues present at all N-glycan sites. The United States 
patent numbers that protect this product are 5,236,838 and 
5,549,892.
Purified imiglucerase is a monomeric glycoprotein of 
497 amino acids, containing four N-linked glycosylation sites 
(Mr = 60,430): it differs from placental glucocerebrosidase by 
one amino acid at position 495, where histidine is substituted 
for arginine (H495R). The oligosaccharide chains at the gly-
cosylation sites have been modified to terminate in mannose 
sugars. The modified carbohydrate structures on imiglucerase 
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are modified in vitro and differ slightly from those on placental 
glucocerebrosidase. Unlike alglucerase, which was supplied as 
a protein solution containing a mild solubilizing agent and was 
partially contaminated by proteins such as human chorionic 
gonadotrophin, Cerezyme is supplied as a pure lyophilized 
product and is reconstituted in water for clinical use.
Clinical outcomes
Clinical trials of alglucerase
As already described in detail, the first clinical trial was 
published by Barton et al.3 This was an uncontrolled study 
in twelve patients (four adults and eight children), on a dose 
of 60 U/kg every other week of the macrophage-targeted, 
placentally derived enzyme over a period of 9–12 months. 
The treatment received approval for marketing authorization 
as Ceredase by the US Food and Drug Administration (FDA) 
in the same year. It is of interest to compare the trial design 
that was sufficient to permit approval for the marketing of 
Ceredase in 1991 with the more onerous requirements placed 
upon companies bringing ultra-orphan products to market 
more recently. While the burden of proof required to meet 
FDA and European Medicines Agency (EMA) standards 
has increased with the growing acceptance of the dogma of 
“evidence-based medicine,” and the consequent demand for 
double-blind, placebo-controlled trials in patients naïve to 
therapy and crossover trials in patients already on established 
treatments, it can still be argued that the simple open-label 
design of the original alglucerase trial was sufficient, given 
the striking and self-evident efficacy on the primary focus of 
the disease (splenic enlargement with hypersplenism).
Clinical trials of imiglucerase
A randomized clinical trial comparing the placenta-derived 
Ceredase with the recombinant Cerezyme was reported 
by Grabowski et al125 in 1995. Fifteen patients with type 1 
disease, naïve to specific therapy, were randomized to each 
treatment. The response in terms of organ volumes, hema-
tologic parameters, and biomarkers (angiotensin-converting 
enzyme inhibitors and acid phosphatase activities) were not 
significantly different. As a result of this trial, the treatments 
were regarded as equivalent. The prevalence of antibody 
responses was greater in the case of the Ceredase-treated 
patients (40% versus 20%).
Therapeutic targeting of human  
glucocerebrosidase in vivo
Selectivity of mannose-terminated human   glucocerebrosidase 
for macrophages in target organs was later explored in 
  living patients with Gaucher disease in a γ-scintigraphic 
study   carried out in eight subjects by Pramod Mistry and 
colleagues in the senior author’s laboratory, Cambridge, 
UK.126 Human placental and recombinant preparations (alg-
lucerase and imiglucerase) behaved identically in these stud-
ies. The emission of medium-energy (159 keV) γ-rays from 
this relatively short-lived isotope is well suited for whole-
body γ-scintigraphy; moreover, use of the mild and indirect 
  Bolton-Hunter labeling technique maintained the functional 
and enzymatic integrity of the carrier-free pure proteins.
The plasma half-life of tracer doses (∼0.25 mg [8 U]), 
carrier-free human β-glucocerebrosidase was very short, with 
a mean of 4.7 ± 1 minutes and brisk uptake into the liver (34%), 
spleen (16%), and affected bone marrow lesions; splenic 
uptake ranged from only 2.7% in a healthy control subject but 
was 30% of the administered dose in a patient with massive 
(.3 kg) splenomegaly.126 The distribution corresponds to 
the predicted population of macrophages in these organs and 
demonstrates the presence of a high avidity system in vivo. 
Tissue uptake was saturable, so that the clearance from the 
circulation increased from 4.5 to 12 minutes at a repeat dose 
of 80 mg (2800 U; 35 U/kg; 1 mg/kg body weight) in one 
subject with Gaucher disease: exponential loss of enzymatic 
activity and tracer from the plasma compartment declined in 
parallel for 40 minutes, indicating the protein ligand remained 
intact in the circulation. Clearance of the label from the 
tissues, as judged scintigraphically, was biphasic: about one-
half disappeared rapidly with a half-life of 1.4–1.8 hours; the 
slower component had a half-life of 34–42 hours.
An enriched population of Gaucher cells was isolated 
from the spleens of two patients treated surgically for 
intractable hypersplenism; in one patient, a few hours after 
administration of 11.4 mg (5 U/kg) therapeutic enzyme, 
acid β-glucosidase activity was restored to a mean of 
7.2 nmol/h/mg protein (within the reference range for 
monocyte-derived human macrophages, 9.2 ± 2.4 nmol/h/mg 
protein; this was unlike the splenic Gaucher cells identically 
prepared from a patient who did not receive enzyme treat-
ment immediately before surgery (0.29 nmol/h/mg protein). 
Acid β-glucosidase activity in a splenic homogenate prepared 
from a patient splenectomized for hemolytic anemia due to 
pyruvate kinase deficiency was 2.31 nmol/h/mg. Appreciable 
targeting of the pathological macrophages in the spleen was 
confirmed by showing that while the ∼25-fold enrichment 
of enzyme activity occurred in the Gaucher cells, activity 
in the whole splenic homogenate prepared from this patient 
was enriched only twofold. These studies demonstrated 
avid and saturable uptake of mannose-terminated human 
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β-glucocerebrosidase by macrophages in vivo and they 
provide confirmatory basis for therapeutic enzyme targeting 
in living patients with Gaucher disease.126
Further clinical research
Clinical investigations have focused on (1) determining 
the minimum amount of enzyme required to bring about 
a clinical response; (2) determining the minimum quantity 
of enzyme necessary to maintain patients in good health 
once they have responded to treatment; (3) the best strata-
gem to establish the greatest long-term therapeutic benefit; 
(4)   determining the optimum frequency of administration of 
enzyme; (5) examining the effects of enzyme replacement 
therapy in patients with type 3 Gaucher (chronic neuronop-
athic) disease; and (6) the long-term outcomes of the disease 
in its treated state.
Registry data
The International Collaborative Gaucher Group   Gaucher 
  Registry – commonly referred to as the Gaucher   Registry – has 
been in operation since 1991 with a remit to collect data on 
safety and clinical outcomes of patients on enzyme replace-
ment therapy. The Genzyme Corporation supports the 
registry with funding for a permanent administrative staff 
and statistical support. A panel of practicing physicians, 
experienced in the field, provides independent oversight 
and governance. The registry is open to patients who are not 
on specific treatments and to patients receiving medication 
produced by other companies.
Publications from the registry have contributed to the 
knowledge of the range of clinical features of Gaucher   disease, 
the mutations in the GBA gene associated with disease, and 
the therapeutic effects of enzyme   supplementation. The 
process of contributing to this collaborative project has, in 
the authors’ view, brought physicians with differing views 
on the condition together and has in an indirect way helped 
consolidate the position of the Genzyme company as a 
dominant force in the Gaucher disease field.
The registry holds data on about 6500 patients at the time 
of writing. Although the data for individual patients are often 
incomplete, the number of patients involved permits analysis 
that would be difficult to achieve in any other way.
Treatment response has been analyzed for subgroups 
of patients. The pediatric data have shown the expected 
improvements in hematological parameters and organ 
volumes, but they have also shown dramatic catch-up 
growth75 and achievement of normal peak bone mass. 
Using data obtained from the international Gaucher disease 
  registry – initiated and supported by Genzyme – Charrow 
et al139 have shown a dramatic reduction in the incidence of 
the typical bone crises after starting enzyme therapy.
Sophisticated statistical modeling can partly compensate 
for missing data and can to a certain extent control for the 
kind of systematic bias that can occur in voluntary registry 
studies. An instructive example of a study employing these 
methods involved the assessment of dose-response relation-
ships in registry patients.135 A system known as propensity 
scoring was used to determine the predictors of prescribed 
dose of Cerezyme in the registry. This was then used to match 
groups of patients who shared the propensity score or, in 
other words, those who shared the factors that are associated 
with dose, but in fact differed in the actual dose used. About 
120 patients, all of who had relatively complete longitudinal 
data and who did not differ in parameters of disease severity, 
were allocated to one of three dose groups. Patients receiving 
the higher doses showed earlier and more complete response 
to therapy in platelet count, hemoglobin concentration, and 
splenic and hepatic volumes. The study design addressed 
the principle bias that had confounded earlier attempts: 
that patients with more severe disease may respond more 
in   relative terms, regardless of dose, but may be allocated a 
higher dose because of the severity of their disease.
Enzyme therapy in pregnancy
Enzyme therapy during pregnancy is associated with a 
  reduction in incidence of bone complications, spontaneous 
abortion, and bleeding episodes. No treatment-related adverse 
effects on the fetus or neonate have been reported.52 In recent 
years, despite the usual and understandable reluctance to 
prescribe during pregnancy, the climate of opinion has shifted 
towards active treatment with enzyme therapy throughout 
pregnancy, particularly in women receiving therapy before 
conception. Clearly, this remains a matter for individual 
discussion between the patient and her physician.
The therapeutic position
Safety
Antibody responses to the placental enzyme therapy occurred 
in about 13% of patients.121 Of 262 patients studied, an immu-
nologic response was confirmed in 32 individuals. Symptoms 
suggestive of immediate hypersensitivity were reported in 
14 of the 262 patients, but nine of these exhibited an IgG 
response, and none demonstrated a specific IgE response. 
Starzyk et al140 published a report on the pharmacovigilance 
data collected by the Genzyme Corporation between 1994 
and 2004 that related to imiglucerase. IgG antibody responses 
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were detected in 15% of patients. Adverse events that were 
considered related to the medication included pyrexia, chills, 
pruritus, rashes, urticaria, and dyspnea associated with 
  infusions. These were generally infrequent, mild to moderate 
in intensity, and self-limiting. Only three patients needed to 
discontinue therapy as a result of infusion reactions.
Supportive treatments
Palliative and supportive treatment remains necessary, 
especially for patients who do not have access to treatment 
or for whom treatment was available late in the evolution of 
their disease. The neurological features continue to evade 
specific treatment.
Bone disease is the major cause of morbidity25 and 
orthopedic procedures are frequently needed, including 
primary joint replacement and revision joint replacement 
in this relatively young group of patients. A proportion of 
patients have undergone multiple joint replacements at sev-
eral sites. Osteotomy of the femoral neck and the acetabu-
lum has been used in young patients to realign the hip joint 
  following osteonecrosis. Spinal corrective surgery in patients 
who develop kyphoscoliosis may be so severe as to require 
insertion of metal Harrington rods, usually in the context of 
type 3 disease.
Bisphosphonates have a role in the supportive manage-
ment of Gaucher disease affecting the skeleton.141 There is 
evidence that enzyme therapy improves osteopenia, although 
the response may not be evident for several years. Oral bis-
phosphonate medication can increase bone mineral density in 
patients already on enzyme therapy.142 The effect of enzyme 
treatment on osteopenia may, in addition, be age dependent143 
and osteopenia may transiently worsen after initiation of 
treatment as normal hematopoietic marrow replaces marrow 
containing pathological macrophages and accompanying 
cells.144 Antiresorptive therapy with oral bisphosphonates in 
high doses rapidly increases bone density in Gaucher disease 
patients who are simultaneously treated with enzyme infu-
sions,142 but the effect of bisphosphonate treatment on bone 
strength145 or fracture risk is unknown.
While parenteral administration of more potent 
  bisphosphonates (eg, pamidronate) may ameliorate   Gaucher 
bone pain and skeletal disease in children,146 except in 
  children or young adults with vertebral collapse and recurrent 
pathological fractures due to severe osteoporosis,147 there is 
insufficient evidence to recommend general use of adjunc-
tive bisphosphonates in Gaucher disease. Osteonecrosis of 
the jaw has yet to be reported in Gaucher patients receiving 
potent bisphosphonates.
Gallbladder surgery is very frequently necessary in adults 
with Gaucher disease, in whom the frequency of   cholelithiasis 
exceeds the high background rate in a matched but oth-
erwise healthy population. First reported by   Rosenbaum 
and Sidransky,148 others have shown that Gaucher patients 
commonly have symptomatic gallstones, and that the bile 
composition in Gaucher disease is abnormal, with lithogenic 
properties that predispose to the formation of cholesterol-
rich calculi.149
Liver transplantation has occasionally been required to 
rescue patients from end-stage liver failure or hepatopul-
monary syndrome. Specialized medical treatment with 
pulmonary arterial vasodilators is occasionally required to 
ameliorate pulmonary hypertension, which is associated with 
  splenectomy and cirrhosis; it may also follow hepatopulmo-
nary syndrome in which high-dose enzyme therapy has, in 
some cases, been reported to be beneficial.150
Excessive operative bleeding as a result of thrombo-
cytopenia, coagulopathy, or platelet function defects com-
monly complicates surgical intervention. The authors advise 
that Gaucher patients, particularly those who are asplenic, 
should have platelet function tests carried out before elective 
surgery. Postoperative sepsis, particularly osteomyelitis, is 
an additional concern. Close liaison between the surgeon 




Imiglucerase has proved to be a highly successful drug 
for the treatment of adults and children with Gaucher 
disease – including patients with the chronic neuronopathic 
type 3 variant, in whom it improves quality of life, 
hematological manifestations, and visceromegaly. The 
hematological and inflammatory manifestations of Gaucher 
disease are thus reversible, but skeletal collapse, necrotic 
tissue injury with fibrosis, and cell death are challenges that 
mandate the need for access to treatment as early as possible; 
issues concerning access also apply to foci of disease within 
the individual patient, particularly in the nervous system and 
skeleton, which hitherto have proved refractory to therapy. 
Some patients receiving full doses of imiglucerase for many 
years have persistent symptoms and recurrent disability due 
to focal disease at sanctuary sites within the viscera and bone 
marrow; the blood–brain barrier is a major obstacle to the 
treatment of the neurological manifestations.
Enzyme therapy also has disadvantages: manufacture 
is costly and intravenous infusions are inconvenient to 
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  administer. Infusions of drug, usually given every 2–4 weeks, 
may be painful for some patients and they may render patients 
unnecessarily dependent on hospital services; young children 
may develop a fear of needles and an aversion to the treatment. 
In countries with underdeveloped systems of health care, 
intravenous infusion may constitute an elaborate procedure, 
particularly in those where clean needles and appropriate 
equipment for administration of the drug under safe circum-
stances in public health services are not easily available.
These factors represent a genuine unmet medical need 
and in an attempt to develop the therapeutic arena,   companies 
have investigated nonbiologic agents for the treatment of 
Gaucher disease, with a competitive emphasis on orally 
active molecules. Ultimately, therapeutic compounds that are 
able safely to enter the brain and nervous system by travers-
ing the blood–brain barrier will offer immense benefit and 
will revolutionize the field.
Miglustat
The first alternative product to be approved (in 2002) for 
Gaucher disease was the iminosugar miglustat (Zavesca®; 
Actelion, Basel, Switzerland). In the principal phase 3 trial151 
therapeutic benefit was seen in liver and spleen volume and in 
platelet count; in those patients with anemia at entry, salutary 
responses in   hemoglobin concentration occurred. The effect 
size was less than one would normally predict for untreated 
adult patients with nonsevere Gaucher disease receiving 
enzyme treatment, but sustained therapeutic effects were 
observed in a follow-up study in 18 of 22 eligible patients 
taking the agent for up to 3 years.152
Adverse effects are common. Diarrhea and weight loss 
can be addressed by dietary modification and can result 
from inhibition of intestinal disaccharidases. Tremor is also 
frequent, but rarely disabling; in most patients it has resolved 
spontaneously. Several cases of peripheral neuropathy have 
been described in the literature151 and reported in the safety 
registry associated with this medicine. A European consensus 
statement, recognizing that both imiglucerase and miglustat 
were licensed for the treatment of Gaucher disease, reviewed 
their therapeutic status and developed consensus guidelines 
for the use of this oral agent as a second-line agent in patients 
with mild to moderate Gaucher disease who are unable or 
unwilling to take enzyme therapy. The agent affects male 
fertility in mice and although no genotoxicity has been 
demonstrated, miglustat should not be taken by patients in 
the reproductive age group. Miglustat is not licensed for use 
in children.153 The results of a 2-year prospective, open-label 
noninferiority study to evaluate miglustat as a maintenance 
treatment in adult patients with type 1 Gaucher disease who 
have had their disease controlled by imiglucerase are shortly 
to be published.
velaglucerase
Velaglucerase alfa (VPRIV) was licensed in 2010 on the basis 
of an extensive clinical trial program. This protein is produced 
by specific gene activation in a cell line derived from a human 
fibrosarcoma; unlike imiglucerase, but like alglucerase, 
the protein has the wild-type human glucocerebrosidase 
sequence of amino acids and is decorated by mannose resi-
dues. The glycosylation is modified during the cell culture by 
the use of kifunensine, a potent and selective inhibitor of the 
glycoprotein processing mannosidase 1. As a result, there is 
a complete shift in the structure of the N-linked oligosaccha-
rides from complex chains to immature highly mannosylated 
structures, so that the therapeutic protein obtained from the 
fibrosarcoma cells does not require further modification 
to remodel its carbohydrate signal for macrophage uptake 
because it displays an extensive array of terminal mannose 
sugars. Claims have been made for greater cellular uptake as 
a result of greater mannose display,154 but these have also been 
disputed.155 In clinical use, the therapeutic effect appears to be 
equivalent to imiglucerase at the doses commonly used and 
using the usual end points of organ volumes, platelet count, 
hemoglobin, and biomarkers.156–158 Claims are also made 
for reduced immunogenicity, but this requires independent 
analytical verification and clinical assessment.
Taliglucerase
A further enzyme preparation, taliglucerase alfa, is in late 
clinical development and is under review by the FDA and 
EMA at the time of writing. It is produced by conven-
tional recombinant technology, but in plant (carrot) cells 
in culture in disposable plastic containers. The amino acid 
sequence is modified at the N- and C-termini to add short 
tags of 3 and 7 amino acids, respectively, which target the 
protein to the vacuole of the cell to aid harvesting. The 
recombinant plant-derived enzyme is targeted to the storage 
vacuoles, using a plant-specific C-terminal sorting signal, 
the recombinant human glucocerebrosidase expressed in 
the carrot cells displays terminal mannose residues on its 
complex glycans, presumably as a result of the activity of a 
plant vacuolar enzyme that modifies complex glycans. The 
manufacturers claim greater uptake into macrophages159 
than Cerezyme, although researchers at Genzyme reported 
that human β-glucosylceramidase molecules with differ-
ent   oligomannose chain length had paradoxical effects on 
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  macrophage uptake155 – it was found the presence of more 
than two mannose residues impaired the rate of uptake. 
Moreover, large mannosylated structures with a mean 
number of mannose residues exceeding the mean of 14 per 
molecule reported in imiglucerase had increased affinity for 
the mannose-binding lectin in serum – a humoral component 
of the innate immune system. Taliglucerase also harbors 
sequences of pentose and hexose sugars such as xylose 
and fucose, which do not typically occur in mammalian 
glycoproteins but enable the protein to be secreted from the 
vacuolar   pathway in plant cells. Despite these differences, 
the   expression and production system does not encounter 
the regulatory hurdles associated with bioreactor-based 
systems requiring revalidation with every change to a larger 
  bioreactor. Thus the manufacturing platform is inherently 
flexible and has the potential to respond rapidly to increased 
demands for production.
Safety studies and phase 1 trial results have not revealed 
any early safety concerns.160 Recent data from a pivotal phase 
3 clinical trial suggest similar efficacy to imiglucerase in 
the doses used and over the period of the trial.   Twenty-nine 
patients completed the protocol over 20 months with no seri-
ous adverse events; two patients developed non-neutralizing 
IgG antibodies; and two others developed hypersensitivity 
reactions. Statistically significant spleen reduction was 
achieved at 9 months in two dose regimens (both P , 0.0001) 
and in all secondary efficacy end-point measures, except 
platelet counts at the lower dose.161 To date, no clear   evidence 
of increased immunogenicity has emerged, despite the differ-
ence in amino acid sequence and variant glycan structures that 
reflect the requirements for secretion by plant cell systems.
Eliglustat tartrate
Eliglustat tartrate is another orally active inhibitor 
of uridine diphosphate glucosylceramide synthetase 
(uridine diphosphate-glucose: N-acylsphingosine transferase), 
the enzyme which catalyzes the first committed step in the 
biosynthesis of glycosphingolipids that are derived from 
β-glucosylceramide (glucocerebroside). Eliglustat is currently 
under late-stage clinical development for Gaucher disease by 
the Genzyme Corporation. The compound is one of a series 
of ceramide analogues that inhibit glucocerebroside synthase 
and were originally based on 1-phenyl-2-decanoylamino-
3-morpholino-1-propanol and its congeners.162,163 These 
molecules mimic the transition state of the enzyme and are 
highly potent and selective inhibitors (Ki ≈ 25 nmol/L).164 
However, it was found that the original structures have 
dual activity towards glucocerebroside synthase as well as 
1-O-acylceramide   synthase; they are toxic in cell cultures 
and this was attributable to increased intracellular ceramide 
concentrations and inhibition of cell growth. The scaffold 
was thus refined to increase potency for inhibiting formation 
of glucosylceramide while reducing the inhibitory effect on 
1-O-acylceramide synthase, which leads to increased steady-
state levels of intracellular ceramide.165,166
In healthy volunteers, plasma glucocerebroside con-
centrations diminished rapidly after dosing with eliglus-
tat tartrate.167 In phase 2 clinical trials in patients with 
type 1 (non-neuronopathic) Gaucher disease, twice-daily 
oral administration had salutary effects on blood counts, 
and spleen and liver volumes were consistently reduced.168 
Phase 2 clinical trial data showing continuing efficacy are 
currently available from patients receiving the agent for over 
3 years. Investigators with experience in the treatment of 
Gaucher disease consider that the therapeutic activity on the 
hematological and visceral manifestations compares favor-
ably with that of licensed doses of imiglucerase157,169 and 
velaglucerase. Moreover, in the trial data currently released 
into the   public domain, the majority of patients have shown 
improved bone mineral density, correction of the patho-
logical “dark” signal on T1-weighted magnetic resonance 
imaging of bone marrow, and normalization of plasma 
glucocerebroside and ganglioside GM3   concentrations. 
The drug is well tolerated and appears so far to have few 
unwanted effects; it shows a wide therapeutic ratio (.30). 
Very high plasma concentrations (.250 ng/mL) of eliglustat 
tartrate are associated with prolongation of the QTc interval 
on electrocardiography and the potential for ventricular or 
supraventricular   tachyarrhythmia. The principal route for 
metabolism involves CYP2D6 with minor contributions 
from the CYP3A4 isozyme; there is considerable popula-
tion variation in the metabolism, suggesting that prudent 
monitoring would be advisable for patients taking eliglustat 
tartrate, especially those taking other agents that interact with 
the CYP2D6 system. Such drugs are numerous and include 
paroxetine, ketoconazole, and rifampicin.166
Provided the long-term safety and monitoring profile of 
eliglustat tartrate remains secure, there is little doubt that 
orally active eliglustat tartrate, which has a potent   inhibitory 
action on the primary identified molecular target for type 1 
Gaucher disease and other glycosphingolipidoses, will fulfill 
high expectations for clinical efficacy and use in adults with 
the disorder. The appropriate use of this novel oral agent 
in the context of its therapeutic profile and age range of 
patients remains a matter for discussion, but with unknown 
reproductive effects, it seems likely that its use in young 
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persons will be restricted. With the recommendation for 
initial pharmacokinetic evaluation to ensure that appropriate 
plasma concentrations are established, it seems likely that, if 
eliglustat is approved for marketing (as it is expected to be), 
it will find its use within the context of centers with specialist 
experience of Gaucher disease.
Access to treatment
As capitalist economies reward perceived value, they should 
aspire to reward the value that the perception of health – a 
common human necessity – brings to members of the 
electorate. In most developed companies, it has long been 
recognized that the unregulated pursuit of profit without 
social investment is schismatic and necessarily short-lived. 
Moreover, capitalism can be legitimized by taxation directed 
to key aspects of health care: diagnostic services, medicines 
provision, and public health measures.
The introduction of orphan drug legislation has ensured 
that patients with rare diseases now receive more welcome 
attention through the agency of orphan drug legislation, 
and in many cases gain real benefit as a result of   pioneering 
humane initiatives. However, the exception of Gaucher 
disease makes for bad law; the current model will need 
reviewing if it is to deliver value across the thousands of 
individually rare diseases in whole populations.
With the need to overcome numerous scientific and 
real-life clinical obstacles, unusual levels of motivation 
are needed to develop orphan or ultra-orphan agents, and 
beyond mandatory pharmacovigilance monitoring and fulfill-
ment of postlicensing commitments, there is little incentive 
for the victorious company to invest further. In essence, 
orphan drug legislation is attractive because it is tantaliz-
ingly   anticompetitive.170 In the ordinary course of events 
biotechnology companies come to believe that therapeutic 
research must be retransferred to the academic quarters from 
which, in most cases, it has emerged. Indeed, often for such 
investment to occur, unpredicted competition and the fear of 
loss of commercial primacy need to be felt. Now, with the 
recognition of vesivirus, the survival of any given biologic, 
including therapeutic enzymes, has been unexpectedly called 
into question: all now appreciate that there can be no immu-
nity from unexpected manufacturing disasters.
Evolution of the Genzyme 
Corporation in brief
Since 1981, Genzyme grew from a small start-up   company 
with a principal focus on Gaucher disease and other rare 
disorders to become a diversified business with more 
than 12,000 employees worldwide and 2009 revenues of 
$4.5 billion; Genzyme became the world’s third-largest 
biopharmaceutical company. Product diversification and 
development of diagnostic and other services later extended 
to kidney disease, orthopedics, cancer, transplantation, and 
immune disease, as well as diagnostic testing.
Manufacturing difficulties and supply failure
In June 2009, a vesivirus (strain 2117) infection occurred 
in the dedicated bioreactor plant at the principal   production 
facility of the Genzyme Corporation in Allston, MA. 
Although vesiviruses – members of the Caliciviridae 
  family – have not been shown to cause human disease or 
infection, the organism is known to interfere with the growth 
of Chinese hamster ovary cells used in culture to produce 
recombinant proteins. The vesiviral genome contains a single 
linear positive-sense, single-stranded RNA molecule of 
7700   nucleotides. At the Allston facility, company   scientists 
detected the virus in a highly specific assay developed 
after standard tests were unable to identify the cause of the 
production failure. Investigations by Genzyme scientists 
showed retrospectively that this virus had caused reduced 
cell productivity at its Allston and Geel, Belgium, facilities 
in two previous instances in 2008.
Vesivirus 2117 led to a catastrophic shortage of 
Cerezyme – as well as a shortage of the preparation of alpha-
galactosidase A for Fabry disease (Fabrazyme®; Genzyme) – and 
with little inventory remaining, regional difficulties in supply 
persist to the time of writing in March 2012. The world supply 
and manufacture of Fabrazyme remains exiguous and provision 
of Cerezyme remains “hand-to-mouth” as a consequence 
of diminished stocks. By the end of the first quarter of 
the fiscal year in 2010, Genzyme reported a net loss for the 
first quarter of ∼$115 million, compared with net income 
of ∼$196 million in the same period in 2009 – with revenues 
reduced by the limited shipments of Cerezyme and Fabrazyme 
and constraints in product supply. This rapid decline in 
fortunes was compounded by a punitive charge associated 
with a consent decree issued by the FDA regarding the 
Allston   manufacturing plant; this decree required an up-front 
disgorgement of past profits of $175 million for the Allston 
manufacturing facility.   Thereafter, Genzyme was forced 
temporarily to close its Allston plant, leading to the severe 
shortages of Cerezyme (and Fabrazyme for Fabry disease).
In the early phases of the crisis, competing companies 
were contacted by the FDA and EMA and requested to assist 
with the manufacture and delivery of alternatives such as 
velaglucerase alfa and taliglucerase alfa.171




Development of imigluceraseDrug Design, Development and Therapy 2012:6
The discovery of inadequate quality-control systems 
by regulators and the apparently hubristic ignoring of FDA 
demands to improve production facilities, led to further 
difficulties for the Genzyme company. While the loss of 
30% or more of its market share for Cerezyme was a bitter 
blow, the injury to the reputation and perceived standards 
of manufacturing of this former prizewinning and highly 
innovative orphan drug company has been catastrophic. 
The supply crisis for Cerezyme sent the price of Genzyme’s 
shares (stocks) from $84 in 2008 to a low in early 2010 
of $45. At this point Sanofi-Aventis (from May 2011 now 
known as Sanofi SA), a French-based global pharmaceu-
tical company with fortuitous and historical connections 
to Pasteur Mérieux, from which it originated, offered 
$18.5 billion, or $69 a share, to acquire the Genzyme 
Corporation. Genzyme was eventually acquired in February 
2011 by Sanofi-Aventis for approximately $18 billion. The 
Genzyme Corporation is now a wholly owned subsidiary 
of Sanofi SA.
Sanofi SA is headquartered in Paris: it has activities in 
cardiovascular and central nervous system diseases,   diabetes, 
internal medicine, oncology, thrombosis, and vaccines 
(through its subsidiary Sanofi Pasteur it is the world’s larg-
est vaccine manufacturer). Despite this immense profile of 
activities, Sanofi clearly considers the developmental plans 
for Genzyme’s hierarchy of drugs attractive for long-term 
investment. Genzyme’s innovative program of substrate 
inhibiting drugs – including eliglustat tartrate for Gaucher 
disease – is prominent within its portfolio.166
Conclusions and future prospects
The treatment of Gaucher disease is a paradigm example 
of achievement in the treatment of human diseases 
(see Walsh172): based on many years of clinical and labora-
tory research and studies of the molecular cell biology of 
the lysosome, it has led the way in the specific targeting of 
therapeutic proteins to sites of action within diseased tissues. 
Potential concerns that therapeutic proteins would invoke 
intolerable immune reactions have, in the main, proved to 
be overrated: while most natural and recombinant biologic 
agents induce immune responses – in the case of alglucerase, 
imiglucerase, and other biologics – in general these are well 
tolerated.
The subsequent development of a recombinant human 
protein – imiglucerase – that can readily access cells and 
has the potential for manufacture in almost unlimited 
quantities to prevent or reverse the manifestations of 
disease in thousands of patients worldwide is a prodigious 
achievement. This success, and the attendant spectacular 
commercialization of a biologic agent for an ultra-orphan 
disease, has stimulated much productive activity in the field. 
In the small field of Gaucher disease this has led to the 
discovery of alternative means to treat the condition with 
innovative inhibitors of glycosphingolipid biosynthesis – 
and the accompanying potential for related molecules to 
penetrate the blood–brain barrier. Not only is it now pos-
sible to utilize targeting stratagems to augment the activity 
of defective enzymes within cells but also the potential to 
deliver proteins to intracelluar targets and modify their 
actions offers burgeoning opportunities for therapeutic 
development in other diseases.
Lessons that may be learned
In the hope that future enterprise may benefit, the authors 
disclose an interpretation of the factors which appear 
to favor sustained development in the orphan disease 
field.
We argue that the therapeutic and commercial success of 
imiglucerase may be attributed to the fortuitous combina-
tion of several elements.
1.  A disease that is now known to be largely reversible, at 
least in relation to the hematological and visceral features 
as well as some of its bone manifestations. Unfortu-
nately, the neuronopathic features of Gaucher disease 
remain a true unmet medical need.
2.  A disease, the response to treatment of which, may be 
readily monitored.
3.  A prolonged odyssey of scientific development that cul-
minated in specific targeting of the drug to the restricted 
population of cells of interest.
4.  Incentives to drug development provided by orphan drug 
legislation.
5.  Focused, dynamic commercial exploitation of a new 
therapeutic market.
Finally, a critical – but often unacknowledged –   condition 
for success is the availability of not only a scientific plat-
form but also sufficient resources and investment to take 
the risk. In the case of enzyme therapy for Gaucher disease, 
support came from government sources (the NIH), patients 
and their families (through the National Gaucher Founda-
tion), and investors. Much of the enabling technology was 
in fact financial, and a key event, at the time, was a fusion 
engineered between unlikely partners.
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After the success of imiglucerase, some, even within 
the Genzyme organization, might have lost sight of the long 
scientific gestation of imiglucerase and assumed that its 
success could readily be replicated in other lysosomal dis-
eases. As a result, therapeutic development programs were 
accelerated in diseases less amenable to correction. In Fabry 
disease, Pompe disease, and the mucopolysaccharidoses, the 
cells of interest are the principal structural and functional 
components of the affected organs – renal glomerular cells, 
cardiomyocytes, and so forth. These cells are often postmi-
totic or are not readily replaced from stem cell pools. The 
diseases progress through cell death or fibrosis, which are 
not normally considered reversible in the same way that 
pathological storage and its effects in tissue macrophages 
is reversible. To date,   targeting these cells has depended on 
the display of mannose 6-phosphate residues and uptake by 
the cognate receptors, which are expressed in low number 
on the plasma membrane in many cell types.
Because orphan drug legislation provided market exclu-
sivity to the first agent approved, the advent of competition 
from other biotechnology firms made a “race for the line” 
inevitable. In the instance of Fabry disease, Fabrazyme 
and Replagal® (then TKT Inc, now Shire Human Genetic 
Therapies) were approved in Europe by the EMA (then the 
European Agency for the Evaluation of Medicinal Products) 
on the same day in 2001 through a legislative quirk (the basis 
of which remains mysterious to the authors). Thus, in this 
winner-takes-all environment, drug development could no 
longer be allowed to take 20 years. It may be argued that the 
aim of drug development in the orphan disease area became 
to produce an agent adequate to meet the needs of regula-
tory approval in the shortest possible time, rather than to 
achieve a truly transformative therapy, such as imiglucerase 
has proved to be.
The pressures on biotechnology companies from the 
expectations of patient advocacy groups, shareholders, and 
the marketplace sometimes contributed to accelerated and 
abbreviated preclinical development. A possible example 
here relates to the development of Myozyme® (Genzyme) 
for Pompe disease. The authors envisage a putative scenario 
where Genzyme, under fierce pressure to deliver a therapy 
for patients, some of whom were already in clinical trials, 
chose to pursue the development of a protein with only one 
mannose 6-phosphate group per mole of protein (as com-
pared with six for Fabrazyme, for example). Consequently, 
the dose required to achieve a clinical response was many 
times greater than other enzyme therapies (20 mg/kg every 
other week, compared with 1 mg/kg every other week for 
  Fabrazyme). Producing 20 times as much therapeutic protein 
was a huge manufacturing challenge and may have forced 
Genzyme to focus its production efforts on Myozyme at the 
expense of the established treatments. Thus by the time that 
the vesivirus infection halted production, stocks (inventory) 
of Cerezyme and Fabrazyme had been seriously depleted 
and interruptions in the supply of these agents would have 
been inevitable.
Although orphan drug legislation provides incentives to 
industry, it does not provide any mechanism to ensure that 
the drug will be funded. Niche orphan products are priced 
according to the rarity of the condition, but they are also – the 
authors contend – priced according to what the   manufacturer 
believes the market will bear. With the   expansion in 
  indications for orphan products and the expectation that 
even common diseases such as cancers will be split into rare 
molecular subtypes with a view to orphan designation, the 
market will be able to bear less and less.
The authors urge biopharmaceutical companies, regula-
tors, and funders of niche products to agree a more joined-up 
framework in which regulatory approval would require higher 
standards of transformative clinical efficacy in exchange for 
a more direct route to funding. Equally, approval and funding 
might be made conditional on meaningful long-term efficacy, 
proven in postmarketing studies. Such a funding system would 
reward the sort of scientific and   technical innovation that led 
to the success of imiglucerase but would not encourage further 
a speculative and unsustainable biotechnology boom.
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